Identification and Validation of a Predictive Serological Biomarker Signature for Therapeutic Response to Anti-TNF, Vedolizumab, and Ustekinumab
Development and validation of sampling and rapid assay methods for vedozilumab and ustekinumab therapeutic drug monitoring
Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicals
Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
The value of therapeutic drug monitoring to guide treatment optimisation of biologicals in patients with chronic inflammatory diseases: focus on vedolizumab and ustekinumab
Comparison of short- and long-term effectiveness between anti-TNF and ustekinumab after vedolizumab failure as first-line therapy in Crohn’s disease : a multi-center retrospective cohort study
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study